EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Comparative Expedited Regulatory Programs of U.S Food & Drug Administration and Project Orbis Partners

Lauren T Hotaki iD, Anu Shrestha, Monica P Bennett, Ivelisse L Valdes, Sso H Lee, Yinghua Wang, Dianne Spillman, Tina MacAulay, Melissa Hunt, Julie Gervais, Maral Mafi, Vincent Panetta und 13 weitere

Therapeutic Innovation & Regulatory Science · 2023-07 · 57 (4) · 875-885

DOI: 10.1007/s43441-023-00522-4 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Therapeutic Innovation & Regulatory Science, online erschienen am 18.04.2023. Verfasst von Lauren T Hotaki und 24 weiteren Autor:innen. Beteiligte Einrichtung: U.S. Food and Drug Administration, Oncology Center for Excellence, Silver Spring, MD, USA. lauren.hotaki@fda.hhs.gov. Hauptthemen laut MEDLINE: Neoplasms, Medicine. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 66 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Project Orbis was initiated in May 2019 by the Oncology Center of Excellence to facilitate faster patient access to innovative cancer therapies by providing a framework for concurrent submissions and review of oncology products among international partners. Since its inception, Australia's Therapeutic Goods Administration (TGA), Canada's Health Canada (HC), Singapore's Health Sciences Authority (HSA), Switzerland's Swissmedic (SMC), Brazil's National Health Surveillance Agency (ANVISA), United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA), and most recently Israel's Ministry of Health (IMoH) Medical Technologies, Health Information, Innovation and Research (MTIIR) Directorate, have joined Project Orbis. While each country has its own expedited review pathways to bring promising therapies to patients, there are some similarities and differences in pathways and timelines. FDA's fast-track designation and MHRA's marketing authorization under exceptional circumstances (MAEC) allow non-clinical and limited clinical evidence to support approval under these programs. HC's Extraordinary Use New Drug (EUND) pathway allows granting exceptional use authorization with limited clinical evidence. ANVISA, HSA, MTIIR, and TGA do not have standard pathways that allow non-clinical evidence and limited clinical evidence. While there is no definite regulatory pathway for HSA, the current framework for approval does allow flexibility in the type of data (non-clinical or clinical) required to demonstrate the benefit-risk profile of a product. HSA may register a product if the agency is satisfied that the overall benefit outweighs the risk. All Project Orbis Partner (POP) countries have similar programs to the FDA accelerated approval program except ANVISA. Although HSA and MTIIR do not have defined pathways for accelerated approval programs, there are opportunities to request accelerated approval per these agencies. All POP countries have pathways like the FDA priority review except MHRA. Priority review timelines for new drugs range from 120 to 264 calendar days (cd). Standard review timelines for new drugs range from 180 to 365 cd.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsMedicineUnited StatesHumansDrug ApprovalUnited States Food and Drug AdministrationCanada

Stichwörter der Autor:innen

AcceleratedAuthorizationCollaborationGlobalOncologyPriority

Autor:innen und Institutionen

  • U.S. Food and Drug Administration, Oncology Center for Excellence, Silver Spring, MD, USA. lauren.hotaki@fda.hhs.gov.
  • The George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
  • University of Florida College of Pharmacy, Jacksonville and Gainesville, FL, USA.
  • Division of Regulatory Operations for Oncologic Diseases, Silver Spring, MD, USA.
  • University of Georgia College of Pharmacy, Athens, GA, USA.
  • U.S. Food and Drug Administration, Oncology Center for Excellence, Silver Spring, MD, USA.

ORCID-Profile: Lauren T Hotaki

Zitieren

APA

Hotaki, L. T., Shrestha, A., Bennett, M. P., Valdes, I. L., Lee, S. H., Wang, Y., Spillman, D., MacAulay, T., Hunt, M., Gervais, J., Mafi, M., Panetta, V., Looi, Y. H., Shum, M., Atiek, E., Meincke, R., Rohr, U. P., Ainbinder, D., Boehm-Cagan, A., …, & de Claro, R. A. (2023). Comparative Expedited Regulatory Programs of U.S Food & Drug Administration and Project Orbis Partners. Therapeutic Innovation & Regulatory Science, 57(4), 875-885. https://doi.org/10.1007/s43441-023-00522-4

Vancouver

Hotaki LT, Shrestha A, Bennett MP, Valdes IL, Lee SH, Wang Y, et al. Comparative Expedited Regulatory Programs of U.S Food & Drug Administration and Project Orbis Partners. Therapeutic Innovation & Regulatory Science. 2023;57(4):875-885. doi:10.1007/s43441-023-00522-4

BibTeX
@article{Hotaki2023,
  author = {Hotaki, Lauren T and Shrestha, Anu and Bennett, Monica P and Valdes, Ivelisse L and Lee, Sso H and Wang, Yinghua and Spillman, Dianne and MacAulay, Tina and Hunt, Melissa and Gervais, Julie and Mafi, Maral and Panetta, Vincent and Looi, Yee Hoo and Shum, Michael and Atiek, Eiman and Meincke, Ricarda and Rohr, Ulrich-Peter and Ainbinder, Denize and Boehm-Cagan, Anat and Luxenburg, Osnat and Cerqueira, Mateus Rodrigues and Mouawad, Laila Sofia and Thees, Maria Fernanda Reis E Silva and Prasad, Krishna and de Claro, R Angelo},
  title = {Comparative Expedited Regulatory Programs of U.S Food & Drug Administration and Project Orbis Partners},
  journal = {Therapeutic Innovation & Regulatory Science},
  year = {2023},
  volume = {57},
  number = {4},
  pages = {875--885},
  doi = {10.1007/s43441-023-00522-4}
}
Kostenlos starten →